In the evolving lands Novel radiotracer advantageous for imaging of cape of molecular research, the jr11 peptide has emerged as a focal point for those studying receptor-targeted diagnostics and experimental therapeutic models. As an enthusiast in the field of biochemical research, I have followed the development of this compound closely, specifically its role as a somatostatin receptor 2 (SSTR2) antagonist.
The Case Study #6: [177Lu]Lu-DOTA-JR11: A Somatostatin Mechanism of Action: SSTR2 Antagonism
At its core, DOTA-JR11 is a somatostatin receptor 2 (SSTR2) antagonist. Unlike traditional agonists that internalize into the cell, the somatostatin antagonistic peptide JR11 binds to the receptor without triggering the same internalization pathways. This unique prop Jun 25, 2020 — "For patients with different metastatic patterns, different peptides (DOTA-JR11 versus DOTATATE) should be used. In liver-dominant disease, 68Ga erty is why Satoreotide (JR11) is a SSTR2 antagonist of such high interest; it allows for higher binding capacity and potentially improved imaging contrast in laboratory settings.
When exploring by P Plas · 2022 · Cited by 11 — Somatostatin analogues are an important treatment for well-differentiated, low-grade, gastroenteropancreatic neuroendocrine tumours (GEP-NETs) now. Peptide the somatostatin antagonistic peptide satoreotide tetraxetan (JR11), it is essential to recognize the biochemical precision required. Somatostatin is a small peptide that regulates the function of neuroendocrine cell DOTA-JR11 (Satoreotide tetraxetan) | Sstr2 Antagonist s, and by utilizing an antagonist, researchers can map these receptors with high sensitivity. In my personal observation of current literature, the use of 68 Ga-DOTA-JR11 PET has become a benchmark for evaluating receptor density in various experimental models.
Analytical Applications and Experimental Design
The versatility of this molecule is highlighted by its ability to be radiolabeled. For example, Ga-DOTA-JR derivatives are frequently used in paired imaging studies. Research involving JR11) SPECT/CT in patients with metastatic neuroendocrine tumors—within the scope of strictly observational or pre-clinical study—has provided deep insights into how these agents distribute in by C Eigler · 2024 · Cited by 22 — Another possibility is that the injected amount of DOTA-JR11 (peptide amount) per cycle was approximately 240mg, resulting in specific complex tissue environments.
It is interesting to note that JR11 was introduced as a promising antagonist peptide to overcome the limitations of earlier agonist-based tracers. However, researchers must account for rapid blood clearance profiles, which often dictate the required peptide mass and injection activity. In many studies, a mass of 160–200 µg per injection is utilized to ensure saturation of the target sites.
Comparative Research and Future Directions
When we look at the broader spectrum of peptides, the distinction between ag A radioconjugate consisting of the somatostatin antagonistic peptide satoreotide tetraxetan (JR11) that is linked, via the chelating agent onist and antagonist behavior is critical. While DOTA-JR11 is a somatostatin receptor 2 SSTR2 antagonist, other molecules like DOTA-CXCR4-L is a CXCR4 targeting peptide are being explored in parallel for different receptor profiles, such as those found in glioblastoma research.
Experimental protocols often compare 177)Lu-DOTA-JR11 with other standard radiopharmaceuticals. A key finding in recent data is the favorable therapeutic index observed when using these antagonists, often showing significantly higher absorbed doses in target areas compared to traditional agonists.
A radioconjugate consisting of the somatostatin antagonistic peptide satoreotide tetraxetan (JR11) that is linked, via the chelating agentKey Technical Considerations
For those delving into the synthesis or application of JR11, several factors are vital:
* Chelation Chemistry: The use of DOTA as a chelator is standard, though studies have shown that the diagnostic performance can be sensitive to the choice of chelator, with NODAGA-JR11 sometimes showing unique performance variations.
* Dosimetry: Precise calculation of activity, often in the range of 5.9–13.7 GBq, is necessary to achieve consistent results in experimental models.
* Targeting Efficiency: The efficacy of DOTA-JR11 is heavily dependent on the density of SSTR2 expression, making it a highly specific tool for molecular characterization.
As the field moves forward, the collaboration between developers and research institutions—much like how JCR Pharmaceuticals collaborates with patients and families to understand unmet needs—remains a cornerstone of progress. Whether it is refining the pharmacokinetic profile of the peptide or optimizing the labeling process, the study of JR11 continues to offer a fascinating look at the potential of receptor-specific targeting in advanced biological research.